Rigel Pharmaceuticals announced $58.8 million in total revenues and $8.7 million net income for Q1 2026, driven by a 26% increase in net product sales. The company is progressing its Phase 1b study of R289, targeting lower-risk myelodysplastic syndrome, with dose expansion enrollment expected to complete in H2 2026. Rigel reaffirmed its 2026 revenue guidance of $275-$290 million and anticipates positive net income for the full year while continuing clinical development and business growth.
The Rosen Law Firm is investigating claims that the Flow Foundation provided misleading business information to FLOW cryptocurrency investors. Investors who bought FLOW on or before December 27, 2025, and held it through December 29, 2025, may be eli...
Yili Group held a sustainability forum on August 2, 2026, during the World Dairy Industry Conference in Hohhot, China, gathering over 200 global leaders to discuss sustainable development in dairy farming beyond 2030. The event highlighted Yili's lea...
Yili Group organized a Sustainability Forum during the 2026 World Dairy Industry Conference in Hohhot, China, gathering over 200 international leaders to promote sustainable development in the dairy sector beyond 2030. The event highlighted Yili's le...
The Vanguard S&P 500 ETF (VOO) has reached $1.03 trillion in assets, becoming the first ETF to cross the trillion-dollar mark while charging just 0.03% in fees, significantly lower than the SPDR S&P 500 ETF Trust (SPY) which charges 0.0945%. SPY, the...
The SPDR Portfolio S&P 600 Small Cap ETF (SPSM) provides a lower-cost alternative to the iShares Russell 2000 ETF (IWM) for U.S. small-cap exposure. SPSM tracks an index that requires companies to be profitable, excluding unprofitable firms common in...
